Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 02/27/24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 02/27/24
Apellis Pharmaceuticals, Inc. (APLS) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 02/20/24
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 02/20/24
Has Apellis Pharmaceuticals (APLS) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 02/14/24
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/13/24
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of ApplicationGlobeNewsWire • 01/26/24
Apellis (APLS): Strong Industry, Solid Earnings Estimate RevisionsZacks Investment Research • 01/12/24
Apellis Pharmaceuticals, Inc. (APLS) Soars 14.7%: Is Further Upside Left in the Stock?Zacks Investment Research • 01/09/24
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product RevenuesGlobeNewsWire • 01/08/24
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/02/24
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted ConferenceGlobeNewsWire • 12/28/23
Apellis Pharmaceuticals expects European regulators to reject eye disease drug, sending shares lowerProactive Investors • 12/14/23
Apellis Pharmaceuticals' stock slides 14% after company gets negative trend vote for eye treatment in EuropeMarket Watch • 12/14/23
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European UnionGlobeNewsWire • 12/14/23
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual MeetingGlobeNewsWire • 12/11/23
Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/01/23